Home - VHIO

Dr. Marcos Malumbres receives a CaixaImpulse grant to develop a new generation of drugs against liver cancer

From the laboratory to the patient: the ”la Caixa” Foundation promotes 29 biomedicine and health projects The ”la Caixa” Foundation...

The Paseíco de la Mama 2024 will support the INSP3KTION project

The 14th edition of the solidarity initiative, the Paseíco de la Mama, took place on 28 September. A historic initiative...

Dr. Josep Tabernero en el laboratorio con bata blanca VHIO

Exploring predictive biomarkers of response and resistance to targeted therapy in BRAF-mutated metastatic colorectal cancer

The phase 3 BEACON CRC trial demonstrated that treatment with the BRAF inhibitor encorafenib plus anti-EGFR monoclonal antibody cetuximab, with...

From the laboratory to the patient: the ”la Caixa” Foundation promotes 29 biomedicine and health projects The ”la Caixa” Foundation...

Dr. Marcos Malumbres receives a CaixaImpulse grant to develop a new generation of drugs against liver cancer

The 14th edition of the solidarity initiative, the Paseíco de la Mama, took place on 28 September. A historic initiative...

The Paseíco de la Mama 2024 will support the INSP3KTION project

The phase 3 BEACON CRC trial demonstrated that treatment with the BRAF inhibitor encorafenib plus anti-EGFR monoclonal antibody cetuximab, with...

Exploring predictive biomarkers of response and resistance to targeted therapy in BRAF-mutated metastatic colorectal cancer

Latest News

From the laboratory to the patient: the ”la Caixa” Foundation promotes 29 biomedicine and health projects The ”la Caixa” Foundation...

14 October 2024

Dr. Marcos Malumbres receives a CaixaImpulse grant to develop a new generation of drugs against liver cancer

From the laboratory to the patient: the ”la Caixa” Foundation promotes 29 biomedicine and health projects The ”la Caixa” Foundation...

The 14th edition of the solidarity initiative, the Paseíco de la Mama, took place on 28 September. A historic initiative...

10 October 2024

The Paseíco de la Mama 2024 will support the INSP3KTION project

The 14th edition of the solidarity initiative, the Paseíco de la Mama, took place on 28 September. A historic initiative...

In her latest On target column published by the ESMO Daily Reporter, VHIO’s Elena Garralda discusses the expanding toolbox for immuno-oncology in advanced...

08 October 2024

Elena Garralda’s post-ESMO Congress 2024 column: The expanding toolbox for immuno-oncology

In her latest On target column published by the ESMO Daily Reporter, VHIO’s Elena Garralda discusses the expanding toolbox for immuno-oncology in advanced...

The phase 3 BEACON CRC trial demonstrated that treatment with the BRAF inhibitor encorafenib plus anti-EGFR monoclonal antibody cetuximab, with...

07 October 2024

Exploring predictive biomarkers of response and resistance to targeted therapy in BRAF-mutated metastatic colorectal cancer

The phase 3 BEACON CRC trial demonstrated that treatment with the BRAF inhibitor encorafenib plus anti-EGFR monoclonal antibody cetuximab, with...

VIEW MORE NEWS

Research Programs

PRECLINICAL & TRANSLATIONAL RESEARCH

Cellular Plasticity and Cancer Group

Our group focuses on the interplay between cellular plasticity, stem cells and cancer. Cellular plasticity is recognized today as a critical feature of cancer cells that enables them to transit between different cellular states, including reversible transitions.

PRECLINICAL & TRANSLATIONAL RESEARCH

Growth Factors Group

We focus our research on mechanisms of resistance to targeted therapies and most importantly, how to overcome it by showing that breast cancers resistant to T-DM1, an antibody-drug conjugate ADC)- can be efficiently treated with the second generation ADC SYD985 (Nadal-Serrano et al.).

CORE TECHNOLOGIES

Cancer Genomics Group

VHIO’s Cancer Genomics Group serves as a Core Technology laboratory. We are also dedicated to translational research as well as the development of novel genomic tests.

RESEARCHERS

Elena Garralda

Early Clinical Drug Development Group

We focus on proof-of-concept and proof-of-mechanism trials with targeted therapies, with particular emphasis on cell signaling, cancer stem cells, and…

Teresa Macarulla

Gastrointestinal and Endocrine Tumors Group

Our group continues to play an essential role in developing molecular therapies against GI malignancies. We make important contributions to…

Francesc Bosch

Experimental Hematology Group

VHIO’s Experimental Hematology Group conducts translational, pre-clinical and clinical research on hematological neoplasms of both lymphoid and myeloid origin. Our…

Joaquin Mateo

Prostate Cancer Translational Research Group

Over the last decade, we have witnessed a revolution in the treatment of metastatic castration-resistant prostate cancer (mCRPC) which is…

Events

Saturday 30 November 24 - 08:00 AM Clinical Trials Training Course in Oncology and Hematology

VIEW DETAIL

Friday 29 November 24 - 01:00 PM Clinical Trials Training Course in Oncology and Hematology

VIEW DETAIL

Tuesday 26 November 24 - 08:00 AM PRECEPTORSHIP HEREDITARY CANCER 2024

VIEW DETAIL

Saturday 23 November 24 - 08:00 AM Clinical Trials Training Course in Oncology and Hematology

VIEW DETAIL